Diagnóstico de mieloma múltiple en atención primaria. Sospecha ante una historia clínica adecuada

Becker, 2011, Epidemiology of multiple myeloma, Recent Results Cancer Res, 183, 25, 10.1007/978-3-540-85772-3_2 Berges-Ruiz, 2000, Mieloma múltiple y otras gammapatías monoclonales, FMC-Formación Médica Continuada en Atención Primaria, 7, 437 San Miguel, 2008, Velcade as inicial Standard Therapy in Multiple Myeloma: Assesment with melphalan and prednisone, New Eng J Med, 359, 906, 10.1056/NEJMoa0801479 Kasper D, Braunwald E, Fauci AS, Hauser S, Longo D, Jameson L, et al. Harrison. Manual de Medicina. 16.a ed. Editorial McGraw Hill Interamericana. 2005;70:316–8. Belch, 1991, Effect of daily etidronate on the osteolysis of multiple myeloma, J Clin Oncol, 9, 1397, 10.1200/JCO.1991.9.8.1397 Croucher, 2003, Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival, J Bone Miner Res, 18, 482, 10.1359/jbmr.2003.18.3.482 Gordon, 2002, Pamidonate causes apoptosis of plasma cells in vivo in patients with multiple myeloma, Br J Haemaol, 119, 475, 10.1046/j.1365-2141.2002.03824.x Palumbo, 2008, Thalidomide for treatment of multiple myeloma: ten years later, Blood, 111, 3968, 10.1182/blood-2007-10-117457 Cavo, 2005, Superiorita of thalidomide and dexamethasone over VAD as primary therapy in preparation for autologus transplantation for multiple myeloma, Blood, 106, 35, 10.1182/blood-2005-02-0522 Palumbo, 2006, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomized controlled trial, Lancet, 367, 825, 10.1016/S0140-6736(06)68338-4